Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

NURO

NeuroMetrix (NURO)

NeuroMetrix Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NURO
DateHeureSourceTitreSymboleSociété
31/05/202419h15Edgar (US Regulatory)Form SD - Specialized disclosure reportNASDAQ:NURONeuroMetrix Inc
24/05/202423h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NURONeuroMetrix Inc
15/05/202422h00GlobeNewswire Inc.NeuroMetrix Reports Q1 2024 Business HighlightsNASDAQ:NURONeuroMetrix Inc
15/05/202418h33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NURONeuroMetrix Inc
15/05/202417h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NURONeuroMetrix Inc
19/04/202414h00GlobeNewswire Inc.NeuroMetrix Announces Steps Taken to Enhance Shareholder ValueNASDAQ:NURONeuroMetrix Inc
14/03/202414h00GlobeNewswire Inc.NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral NeuropathyNASDAQ:NURONeuroMetrix Inc
13/03/202414h00GlobeNewswire Inc.NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® FibromyalgiaNASDAQ:NURONeuroMetrix Inc
04/03/202422h12Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NURONeuroMetrix Inc
01/03/202423h07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NURONeuroMetrix Inc
27/02/202422h45Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:NURONeuroMetrix Inc
27/02/202422h00Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:NURONeuroMetrix Inc
22/02/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NURONeuroMetrix Inc
22/02/202413h00GlobeNewswire Inc.NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsNASDAQ:NURONeuroMetrix Inc
20/02/202420h49Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NURONeuroMetrix Inc
15/02/202415h00GlobeNewswire Inc.NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallNASDAQ:NURONeuroMetrix Inc
13/02/202415h00GlobeNewswire Inc.NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueNASDAQ:NURONeuroMetrix Inc
12/12/202315h00GlobeNewswire Inc.NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)NASDAQ:NURONeuroMetrix Inc
05/12/202315h00GlobeNewswire Inc.NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)NASDAQ:NURONeuroMetrix Inc
20/11/202315h00GlobeNewswire Inc.NeuroMetrix Announces One-for-Eight Reverse Stock SplitNASDAQ:NURONeuroMetrix Inc
26/10/202313h00GlobeNewswire Inc.NeuroMetrix Reports Q3 2023 Business HighlightsNASDAQ:NURONeuroMetrix Inc
23/10/202317h13GlobeNewswire Inc.NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference CallNASDAQ:NURONeuroMetrix Inc
02/10/202315h00GlobeNewswire Inc.NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with FibromyalgiaNASDAQ:NURONeuroMetrix Inc
11/09/202313h59Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NURONeuroMetrix Inc
27/07/202313h00GlobeNewswire Inc.NeuroMetrix Reports Q2 2023 Business HighlightsNASDAQ:NURONeuroMetrix Inc
20/07/202319h00GlobeNewswire Inc.NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference CallNASDAQ:NURONeuroMetrix Inc
11/07/202315h00GlobeNewswire Inc.NeuroMetrix Announces Sales Force Expansion for Quell FibromyalgiaNASDAQ:NURONeuroMetrix Inc
28/06/202315h00GlobeNewswire Inc.Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes PatientsNASDAQ:NURONeuroMetrix Inc
07/06/202315h00GlobeNewswire Inc.Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical StudyNASDAQ:NURONeuroMetrix Inc
31/05/202323h22Edgar (US Regulatory)Specialized Disclosure Report (sd)NASDAQ:NURONeuroMetrix Inc
 Showing the most relevant articles for your search:NASDAQ:NURO